349105-56-2Relevant academic research and scientific papers
Pyridazinoquinolinetriones as NMDA glycine-site antagonists with oral antinociceptive activity in a model of neuropathic pain
Bare, Thomas M.,Brown, Dean G.,Horchler, Carey L.,Murphy, Megan,Urbanek, Rebecca A.,Alford, Vernon,Barlaam, Christine,Dyroff, Martin C.,Empfield, James B.,Forst, Janet M.,Herzog, Keith J.,Keith, Richard A.,Kirschner, Alan S.,Lee, Chi-Ming C.,Lewis, Joseph,McLaren, Frances M.,Neilson, Kathy L.,Steelman, Gary B.,Trivedi, Shephali,Vacek, Edward P.,Xiao, Wenhua
, p. 3113 - 3131 (2008/02/06)
A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyi)alkyl]-pyridazino[4,5-b] quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.
PYRAZOLE AMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
-
Page/Page column 39, (2008/06/13)
Pyrazole amides are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
-
Page/Page column 31, (2008/06/13)
The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes
Pyrazole derivatives, compositions containing such compounds and methods of use
-
Page/Page column 23, (2008/06/13)
Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
